Form 4: Lixte Biotechnology Director Rene Bernards Acquires 8,045 Shares Through Stock Options in Lieu of Cash Compensation
SEC Form 4 Filing
Director Rene Bernards acquired 8,045 shares of Lixte Biotechnology through stock options granted in lieu of quarterly cash compensation.
Summary
- On March 31, 2025, Rene Bernards, a director of Lixte Biotechnology Holdings, Inc., acquired 8,045 shares of common stock through the exercise of stock options.
- These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan.
- The options have an exercise price of $1.21 and vested immediately upon grant.
- Bernards directly owns these securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
- Granting options in lieu of cash compensation can conserve the company's cash reserves.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It reflects part of the company's compensation strategy.
Stakeholder Impact
- Shareholders may view the director's increased stake as a positive signal.
- Employees may see this as a standard part of the company's compensation practices.
Key Dates
| Date | Description |
|---|---|
| 06/30/2024 | Options to Purchase Common Stock $ 2.37 |
| 09/30/2024 | Options to Purchase Common Stock $ 1.3 |
| 01/20/2025 | Options to Purchase Common Stock $ 2.33 |
| 03/31/2025 | Date of Earliest Transaction |
| 03/31/2025 | Options to Purchase Common Stock $ 1.21 |
| 04/01/2025 | Signature Date |
| 06/30/2029 | Options to Purchase Common Stock $ 2.37 Expiration Date |
| 09/30/2029 | Options to Purchase Common Stock $ 1.3 Expiration Date |
| 01/20/2030 | Options to Purchase Common Stock $ 2.33 Expiration Date |
| 03/31/2030 | Options to Purchase Common Stock $ 1.21 Expiration Date |
Keywords
stock options, director compensation, Lixte Biotechnology, Form 4, beneficial ownership, Rene Bernards, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.